Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -988.11% is 16% above its 5-year average of -1175.28%, near the high end of its 5-year range (-3225.00%–-272.73%).
19.17% above its 12-month average of -1222.47%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -622.79%.
EBITDA MARGIN
-988.11%
EBITDA MARGIN AVG TTM
-1222.47%
EBITDA MARGIN AVG 3Y
-994.98%
EBITDA MARGIN AVG 5Y
-1175.28%
EBITDA MARGIN AVG 10Y
-1069.13%
EBITDA MARGIN AVG 15Y
-748.30%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+19.17%
CURRENT VS 3Y AVG
+0.69%
CURRENT VS 5Y AVG
+15.93%
CURRENT VS 10Y AVG
+7.58%
CURRENT VS 15Y AVG
-32.05%
CURRENT VS 20Y AVG
N/A
Sintx Technologies, Inc.
Market Cap
$13.73M
EBITDA Margin
-988.11%
TTM Avg
-1222.47%
3Y Avg
-994.98%
5Y Avg
-1175.28%
Market Cap
$13.48M
EBITDA Margin
-839.37%
TTM Avg
-1027.77%
3Y Avg
-3215.79%
5Y Avg
-3215.79%
Market Cap
$14.11M
EBITDA Margin
-23.39%
TTM Avg
-215.41%
3Y Avg
-426.39%
5Y Avg
-612.06%
Market Cap
$14.11M
EBITDA Margin
-855.47%
TTM Avg
-475.86%
3Y Avg
-335.10%
5Y Avg
-307.83%
Market Cap
$13.37M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.62M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sintx Technologies, Inc. (SINT) | $13.73M | -988.11% | -1222.47% | -994.98% | -1175.28% |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.81M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.48M | -839.37% | -1027.77% | -3215.79% | -3215.79% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.11M | -23.39% | -215.41% | -426.39% | -612.06% |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | -855.47% | -475.86% | -335.10% | -307.83% |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.37M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.62M | -34.02% | -37.67% | -64.98% | -56.41% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.03M | -29916.57% | -29916.57% | -29916.57% | -29916.57% |
Gross Margin
-19.7%
EBITDA Margin
-988.1%
Operating Margin
-1053.1%
Net Margin
-1303.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -622.79% |
| 2026-03-31 | -802.89% |
| 2025-12-31 | -632.84% |
| 2025-09-30 | -1541.83% |
| 2025-06-30 | -2512.00% |
| 2025-03-31 | -594.31% |
| 2024-12-31 | -278.04% |
| 2024-09-30 | -1655.59% |
| 2024-06-30 | -609.26% |
| 2024-03-31 | -898.71% |
| 2023-12-31 | -272.73% |
| 2023-09-30 | -1875.60% |
| 2023-06-30 | -638.19% |
| 2023-03-31 | -1341.25% |
| 2022-12-31 | -363.66% |
| 2022-09-30 | -1452.60% |
| 2022-06-30 | -3225.00% |
| 2022-03-31 | -2654.46% |
| 2021-12-31 | -1450.91% |
| 2021-09-30 | -1112.55% |
| 2021-06-30 | -2195.35% |
| 2021-03-31 | -2672.97% |
| 2020-12-31 | -1817.24% |
| 2020-09-30 | -3487.88% |
| 2020-06-30 | -913.24% |
| 2020-03-31 | -837.20% |
| 2019-12-31 | -497.62% |
| 2019-09-30 | -912.14% |
| 2019-06-30 | -888.02% |
| 2019-03-31 | -1591.75% |
| 2018-12-31 | -1666.32% |
| 2018-06-30 | -86.12% |
| 2018-03-31 | -81.27% |
| 2017-12-31 | -192.77% |
| 2017-09-30 | -77.23% |
| 2017-06-30 | -45.48% |
| 2017-03-31 | -57.28% |
| 2016-12-31 | -79.55% |
| 2016-09-30 | -80.85% |
| 2016-06-30 | -49.54% |
| 2016-03-31 | -47.21% |
| 2015-12-31 | -41.61% |
| 2015-09-30 | -46.68% |
| 2015-06-30 | -43.05% |
| 2015-03-31 | -72.80% |
| 2014-12-31 | -63.08% |
| 2014-09-30 | -84.04% |
| 2014-06-30 | -172.02% |
| 2014-03-31 | -60.52% |
| 2013-12-31 | -40.76% |
| 2013-09-30 | -28.18% |
| 2013-06-30 | -35.84% |
| 2013-03-31 | -40.70% |
| 2012-12-31 | -336.22% |
| 2012-09-30 | -18.15% |
